Dynatronics Corporation (DYNT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dynatronics Corporation (DYNT) with AI Score 39/100 (Weak). Dynatronics Corporation designs, develops, manufactures, and sells medical devices for physical therapy, rehabilitation, and pain management. The company filed for Chapter 7 liquidation in January 2026. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Dynatronics Corporation (DYNT) Healthcare & Pipeline Overview
Dynatronics Corporation, operating in the medical device sector, specializes in physical therapy, rehabilitation, and orthopedic products. The company markets its products under various brand names through a network of independent dealers. However, Dynatronics filed for Chapter 7 liquidation in early 2026, introducing substantial uncertainty.
Investment Thesis
Investing in Dynatronics Corporation presents significant risks due to its Chapter 7 liquidation filing in January 2026. The company's negative profit margin of -40.0% and ROE of -127.4% highlight financial instability. While the company has a gross margin of 21.5%, its high debt-to-equity ratio of 225.55 indicates substantial leverage. The company's beta of 0.31 suggests lower volatility compared to the market. Given the liquidation filing, the value of Dynatronics' assets and the potential recovery for investors are highly uncertain. Any investment decision should carefully consider these factors.
Based on FMP financials and quantitative analysis
Key Highlights
- Negative Profit Margin: Dynatronics has a profit margin of -40.0%, indicating the company is not profitable.
- Low Gross Margin: The company's gross margin is 21.5%, which is relatively low for the medical device industry.
- High Debt-to-Equity Ratio: Dynatronics has a debt-to-equity ratio of 225.55, signaling high financial leverage.
- Negative Return on Equity: The company's ROE is -127.4%, reflecting poor profitability relative to equity.
- Chapter 7 Liquidation Filing: Dynatronics filed for Chapter 7 liquidation on January 9, 2026, indicating significant financial distress.
Strengths
- Established brand names (Dynatron, Bird & Cronin, Hausmann).
- Diverse product portfolio.
- Distribution network of independent dealers.
- Long-standing presence in the market.
Weaknesses
- Negative profit margin.
- High debt-to-equity ratio.
- Low gross margin.
- Chapter 7 liquidation filing.
Catalysts
- Ongoing: Chapter 7 liquidation proceedings may lead to asset sales or restructuring.
- Ongoing: Potential for strategic partnerships or acquisitions of Dynatronics' assets by other companies.
Risks
- Ongoing: Chapter 7 liquidation may result in little to no recovery for shareholders.
- Potential: Legal and regulatory risks associated with the liquidation process.
- Potential: Loss of brand reputation and customer relationships.
- Potential: Economic downturns could further impact the company's financial situation.
Growth Opportunities
- Expansion into Telehealth and Remote Monitoring: Dynatronics could explore opportunities in telehealth and remote patient monitoring solutions, leveraging its existing product lines in rehabilitation and pain management. The global telehealth market is projected to reach $55.6 billion by 2027, growing at a CAGR of 25.8% from 2020 to 2027, according to Allied Market Research. This could involve developing connected devices and platforms that allow patients to receive therapy and monitor their progress remotely. However, given the Chapter 7 filing, this opportunity is unlikely to be pursued.
- Development of Advanced Wound Care Products: Dynatronics could invest in the development of advanced wound care products, such as bioactive dressings and negative pressure wound therapy devices. The global advanced wound care market is expected to reach $22.0 billion by 2027, growing at a CAGR of 6.5% from 2020 to 2027, according to a report by MarketsandMarkets. This could involve partnering with research institutions and universities to develop innovative wound care solutions. However, the Chapter 7 filing casts doubt on the company's ability to pursue this avenue.
- Penetration of Emerging Markets: Dynatronics could expand its presence in emerging markets, such as China and India, where there is a growing demand for physical therapy and rehabilitation products. The healthcare market in these countries is expanding rapidly due to rising incomes and increasing access to healthcare services. However, the company's Chapter 7 filing makes international expansion highly improbable.
- Strategic Partnerships and Acquisitions: Dynatronics could pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. This could involve partnering with complementary companies in the medical device industry or acquiring smaller companies with innovative technologies. However, the Chapter 7 filing significantly limits the company's ability to engage in such activities.
- Focus on Sports Medicine and Athletic Training: Dynatronics could focus on the sports medicine and athletic training market, developing specialized products for athletes and sports enthusiasts. The global sports medicine market is expected to reach $8.7 billion by 2025, growing at a CAGR of 7.8% from 2020 to 2025, according to a report by Grand View Research. This could involve partnering with sports teams and athletic organizations to promote its products. However, the Chapter 7 filing makes this strategy difficult to execute.
Opportunities
- Expansion into telehealth and remote monitoring.
- Development of advanced wound care products.
- Penetration of emerging markets.
- Strategic partnerships and acquisitions.
Threats
- Intense competition in the medical device industry.
- Stringent regulatory requirements.
- Technological obsolescence.
- Economic downturns.
- Chapter 7 liquidation proceedings.
Competitive Advantages
- Brand recognition through established brands like Dynatron and Bird & Cronin.
- Established distribution network of independent dealers.
- Diverse product portfolio in physical therapy and rehabilitation.
- Long-standing presence in the medical device industry (founded in 1979).
About DYNT
Dynatronics Corporation, established in 1979 and headquartered in Eagan, Minnesota, has been a player in the medical device industry, focusing on the design, development, manufacturing, marketing, and sales of products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. The company's product portfolio includes orthopedic soft bracing products like cervical collars, arm slings, knee supports, and ankle walkers, alongside physical therapy and rehabilitation equipment such as electrotherapy devices, ultrasound machines, and treatment tables. Dynatronics markets its products under well-known brands like Dynatron, Dynatron Solaris, Bird & Cronin, Hausmann, PROTEAM, and Mammoth. These products are distributed through a network of independent dealers, reaching orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals across the United States, Asia, Latin America, and the Middle East. However, on January 9, 2026, Dynatronics and its affiliates filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Minnesota, signaling a significant turning point for the company and its stakeholders.
What They Do
- Designs and develops medical devices for physical therapy and rehabilitation.
- Manufactures and markets orthopedic soft bracing products.
- Offers therapeutic modality devices, including electrotherapy and ultrasound equipment.
- Provides treatment tables, mat platforms, and other related equipment.
- Sells products under the Dynatron, Bird & Cronin, and Hausmann brand names.
- Distributes products through a network of independent dealers.
- Filed for Chapter 7 liquidation in January 2026.
Business Model
- Designs, manufactures, and sells medical devices and related equipment.
- Generates revenue through sales to orthopedists, physical therapists, and other healthcare professionals.
- Utilizes a network of independent dealers for distribution.
- Markets products under multiple brand names.
Industry Context
Dynatronics Corporation operates within the competitive medical device industry, which is characterized by technological innovation, stringent regulatory requirements, and evolving healthcare practices. The industry includes companies that manufacture a wide range of products, from orthopedic implants to diagnostic equipment. Key trends include the increasing demand for minimally invasive procedures, the growing adoption of telehealth, and the rising prevalence of chronic diseases. Dynatronics focuses on the rehabilitation and pain management segments. However, the company's recent Chapter 7 filing places it in a precarious position within this landscape.
Key Customers
- Orthopedists
- Physical therapists
- Chiropractors
- Athletic trainers
- Sports medicine practitioners
- Clinics and hospitals
Financials
Chart & Info
Dynatronics Corporation (DYNT) stock price: Price data unavailable
Latest News
-
Why Nanobiotix Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
benzinga · Jul 20, 2023
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · May 11, 2023
-
Earnings Scheduled For November 10, 2022
benzinga · Nov 10, 2022
-
Earnings Scheduled For May 13, 2021
· May 13, 2021
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DYNT.
Price Targets
Wall Street price target analysis for DYNT.
MoonshotScore
What does this score mean?
The MoonshotScore rates DYNT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
DYNT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Dynatronics Corporation did not meet the requirements for the higher tiers, OTCQX and OTCQB. Companies in this tier often have limited financial disclosure, and may not be current in their reporting requirements. Trading on the OTC Other tier is significantly different from trading on major exchanges like the NYSE or NASDAQ, which have stricter listing standards and reporting requirements, leading to greater transparency and investor confidence. OTC Other stocks often carry higher risks due to the lack of information and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in DYNT.
- Low liquidity can make it difficult to buy or sell shares.
- The OTC Other tier has minimal regulatory oversight.
- Potential for price manipulation due to low trading volume.
- Chapter 7 liquidation filing introduces significant uncertainty.
- Verify the company's financial statements.
- Assess the company's assets and liabilities.
- Review the Chapter 7 liquidation filings.
- Evaluate the potential recovery for investors.
- Consult with a financial advisor.
- Understand the risks associated with OTC trading.
- Research the company's management and history.
- The company was founded in 1979, indicating a long operating history.
- Dynatronics has established brand names in the medical device industry.
- The company has a distribution network of independent dealers.
- Dynatronics has a diverse product portfolio.
What Investors Ask About Dynatronics Corporation (DYNT)
What does Dynatronics Corporation do?
Dynatronics Corporation designs, develops, manufactures, and sells medical devices and equipment for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. The company offers a range of products, including orthopedic soft bracing products, therapeutic modality devices, and treatment tables. Dynatronics markets its products under brand names such as Dynatron, Bird & Cronin, and Hausmann, distributing them through a network of independent dealers to healthcare professionals and institutions. However, Dynatronics filed for Chapter 7 liquidation in January 2026, indicating significant financial distress and uncertainty about its future operations.
What do analysts say about DYNT stock?
AI analysis is pending for Dynatronics (DYNT). However, given the company's Chapter 7 liquidation filing in January 2026, traditional stock analysis may not be relevant. Investors should focus on the liquidation process and the potential recovery of assets. The company's negative profit margin of -40.0% and high debt-to-equity ratio of 225.55% highlight its financial challenges. Any investment decision should be made with caution and after consulting with a financial advisor.
What are the main risks for DYNT?
The primary risk for Dynatronics (DYNT) is the Chapter 7 liquidation filing, which indicates that the company is unable to pay its debts and is seeking to liquidate its assets. This process may result in little to no recovery for shareholders, as creditors are typically prioritized in bankruptcy proceedings. Other risks include the potential loss of brand reputation, customer relationships, and the impact of economic downturns on the company's financial situation. Investors should carefully consider these risks before making any investment decisions.
What are the key factors to evaluate for DYNT?
Dynatronics Corporation (DYNT) currently holds an AI score of 39/100, indicating low score. Key strength: Established brand names (Dynatron, Bird & Cronin, Hausmann).. Primary risk to monitor: Ongoing: Chapter 7 liquidation may result in little to no recovery for shareholders.. This is not financial advice.
How frequently does DYNT data refresh on this page?
DYNT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DYNT's recent stock price performance?
Recent price movement in Dynatronics Corporation (DYNT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established brand names (Dynatron, Bird & Cronin, Hausmann).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DYNT overvalued or undervalued right now?
Determining whether Dynatronics Corporation (DYNT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DYNT?
Before investing in Dynatronics Corporation (DYNT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change.
- The Chapter 7 liquidation filing introduces significant uncertainty.
- AI analysis is pending.